Previous 10 | Next 10 |
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced today announced the pricing of an underwritten public offering of 13,4...
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common st...
2024-02-09 08:47:48 ET More on Humacyte Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte Financial information for Humacyte Read the full a...
2024-01-24 09:10:00 ET January 24, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of new stocks to watch in Biotech, Defense, Energy and Homebuilder sectors. Today's stocks have been added to Invest...
2024-01-23 17:06:11 ET Gainers: Zoomcar Holdings ( ZCAR ) +8% . Netflix ( NFLX ) +7% . Cricut ( CRCT ) +5% . Tenaya Therapeutics ( TNYA ) +5% . ARS Pharmaceuticals ( SPRY ) +4% . Losers: Humacyte ( HUMA ) -5% . ...
2024-01-09 16:20:04 ET Gainers: WISeKey International ( WKEY ) +14% . MaxCyte ( MXCT ) +8% . Humacyte. ( HUMA ) +8% . Agora ( API ) +6% . Urban Outfitters ( URBN ) +6% . Losers: Grifols ( GRFS ) -9% . Ex...
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Execut...
2023-11-20 19:28:16 ET Summary Humacyte is a developer of implantable regenerative human tissue for trauma and other uses. Their core technology, Human Acellular Vessel, has shown higher rates of patency, lower amputation rates, and lower infection rates compared to synthetic graf...
– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine – – Results showed the HAV had higher rates of patency, and lower rates of amputation and i...
2023-11-15 17:30:35 ET Gainers Veeco Instruments ( VECO ) +5% . Humacyte ( HUMA ) +5% . Expensify ( EXFY ) +5% . ContextLogic ( WISH ) +4% . Tetra Tech ( TTEK ) +4% . Losers: Cisco Systems ( CSCO ) -11% . ...
News, Short Squeeze, Breakout and More Instantly...
Humacyte Inc. Company Name:
HUMA Stock Symbol:
NASDAQ Market:
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Ex...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...